CDKN2D and lymphoma: In vivo mouse experiments established p19INK4d as a canonical tumor suppressor as mice having a complete deletion of CDKN2D gene showed increased frequency of development of wide range of tumors such as pituitary and lung adenomas, lymphomas, hemangiosarcoma, thyroid cancer, and insulinoma [308].